Announcements Trials
Browse Landscape

Phase

Phase NA 17Phase 2 11Phase 1 7Phase 1/2 6Phase EARLY_PHASE1 4Phase 3 3Phase 2/3 2Phase 4 1

Status

Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Carcinoma, Non-Small-Cell Lung 15Squamous Cell Carcinoma of Head and Neck 12Neoplasm Metastasis 12Prostatic Neoplasms 11Neoplasms 10Breast Neoplasms 8Stomach Neoplasms 7Recurrence 7Ovarian Neoplasms 7Myasthenia Gravis 7Lung Neoplasms 7Leukemia, Myeloid, Acute 7Head and Neck Neoplasms 7Colorectal Neoplasms 6Pancreatic Neoplasms 5Oropharyngeal Neoplasms 5Lymphoma, Large B-Cell, Diffuse 5Fatigue 5Urinary Bladder Neoplasms 4Mouth Neoplasms 4Melanoma 4Fallopian Tube Neoplasms 4Endometrial Neoplasms 4Colonic Neoplasms 4Cholangiocarcinoma 4Rectal Neoplasms 3Peritoneal Neoplasms 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Glioblastoma 3

Interventions

pembrolizumab 2Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Skin Neoplasms × 90 days × Clear all
NCT06295809 2026-05-08

INTerpath-007

Merck Sharp & Dohme LLC

Phase 2/3 Terminated
46 enrolled
Dermatologic

Carcinoma, Squamous Cell, Skin Neoplasms

NCT06947928 2026-04-17

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

TuHURA Biosciences, Inc.

Phase 2/3 Recruiting
118 enrolled
Dermatologic

Neoplasm Metastasis, Skin Neoplasms, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡